Header

UZH-Logo

Maintenance Infos

Efficacy and Safety of treatment with biologicals for severe Chronic Rhinosinusitis with Nasal Polyps A systematic review for the EAACI Guidelines


Agache, Ioana; Song, Yang; Alonso‐Coello, Pablo; Vogel, Yasmin; Rocha, Claudio; Solà, Ivan; Santero, Marilina; Akdis, Cezmi; Akdis, Mubeccel; et al; Soyka, Michael B (2021). Efficacy and Safety of treatment with biologicals for severe Chronic Rhinosinusitis with Nasal Polyps A systematic review for the EAACI Guidelines. Allergy, 76(8):2337-2353.

Abstract

This systematic review evaluates the efficacy and safety of biologicals for chronic rhinosinusitis with nasal polyps (CRSwNP) compared to the standard of care.

Pubmed, EMBASE and Cochrane Library were searched for RCTs. Critical and important CRSwNP‐related outcomes were considered. The risk of bias and the certainty of the evidence were assessed using GRADE.RCTs evaluated(dupilumab‐2, omalizumab‐4, mepolizumab‐2, reslizumab‐1) included 1236 adults, with follow‐up 20‐64 weeks.
Dupilumab reduces the need for surgery (NFS)ororal corticosteroid (OCS) use (RR 0.28; 95%CI 0.20‐0.39,moderate certainty) and improves with high certainty smell evaluated with UPSIT score(mean difference (MD) +10.54; 95%CI +9.24 to +11.84) and quality of life (QoL) evaluated with SNOT‐22 (MD ‐19.14; 95%CI ‐22.80 to ‐15.47),with fewer treatment‐related adverse events (TAEs) (RR 0.95; 95%CI 0.89‐1.02, moderate certainty). Omalizumab reduces NFS(RR 0.85; 95%CI 0.78 to 0.92,high certainty), decreases OCS use(RR 0.38; 95%CI 0.10‐1.38, moderate certainty), improves with high certainty smell (MD +3.84; 95%CI +3.64 to +4.04) and QoL (MD ‐15.65; 95%CI ‐16.16 to ‐15.13), withincreasedTAE (RR 1.73; 95%CI 0.60‐5.03,moderate certainty). There is low certainty for mepolizumab reducingNFS (RR 0.78; 95%CI 0.64 to 0.94) andimproving QoL (MD ‐13.3; 95% CI ‐23.93 to ‐2.67) and smell(MD +0.7; 95%CI ‐0.48 to +1.88), with increasedTAEs (RR 1.64; 95%CI 0.41‐6.50). The evidence for reslizumab is very uncertain.

Abstract

This systematic review evaluates the efficacy and safety of biologicals for chronic rhinosinusitis with nasal polyps (CRSwNP) compared to the standard of care.

Pubmed, EMBASE and Cochrane Library were searched for RCTs. Critical and important CRSwNP‐related outcomes were considered. The risk of bias and the certainty of the evidence were assessed using GRADE.RCTs evaluated(dupilumab‐2, omalizumab‐4, mepolizumab‐2, reslizumab‐1) included 1236 adults, with follow‐up 20‐64 weeks.
Dupilumab reduces the need for surgery (NFS)ororal corticosteroid (OCS) use (RR 0.28; 95%CI 0.20‐0.39,moderate certainty) and improves with high certainty smell evaluated with UPSIT score(mean difference (MD) +10.54; 95%CI +9.24 to +11.84) and quality of life (QoL) evaluated with SNOT‐22 (MD ‐19.14; 95%CI ‐22.80 to ‐15.47),with fewer treatment‐related adverse events (TAEs) (RR 0.95; 95%CI 0.89‐1.02, moderate certainty). Omalizumab reduces NFS(RR 0.85; 95%CI 0.78 to 0.92,high certainty), decreases OCS use(RR 0.38; 95%CI 0.10‐1.38, moderate certainty), improves with high certainty smell (MD +3.84; 95%CI +3.64 to +4.04) and QoL (MD ‐15.65; 95%CI ‐16.16 to ‐15.13), withincreasedTAE (RR 1.73; 95%CI 0.60‐5.03,moderate certainty). There is low certainty for mepolizumab reducingNFS (RR 0.78; 95%CI 0.64 to 0.94) andimproving QoL (MD ‐13.3; 95% CI ‐23.93 to ‐2.67) and smell(MD +0.7; 95%CI ‐0.48 to +1.88), with increasedTAEs (RR 1.64; 95%CI 0.41‐6.50). The evidence for reslizumab is very uncertain.

Statistics

Citations

Dimensions.ai Metrics
75 citations in Web of Science®
77 citations in Scopus®
Google Scholar™

Altmetrics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Otorhinolaryngology
04 Faculty of Medicine > Swiss Institute of Allergy and Asthma Research
Dewey Decimal Classification:610 Medicine & health
Scopus Subject Areas:Health Sciences > Immunology and Allergy
Life Sciences > Immunology
Uncontrolled Keywords:Immunology, Immunology and Allergy
Language:English
Date:1 August 2021
Deposited On:12 Mar 2021 15:09
Last Modified:24 Feb 2024 02:48
Publisher:Wiley-Blackwell Publishing, Inc.
ISSN:0105-4538
OA Status:Closed
Free access at:Publisher DOI. An embargo period may apply.
Publisher DOI:https://doi.org/10.1111/all.14809
PubMed ID:33683704
Full text not available from this repository.